Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0NIVXX
ADC Name
LCB14-0110
Synonyms
FS-1502; IKS 014; IKS-014; IKS014; LCB14; Trastuzumab-LC-LBG-MMAF; Herceptin-LC-LBG-MMAF
   Click to Show/Hide
Organization
LegoChem Biosciences, Inc.; Iksuda Therapeutics Ltd.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Drug Status
Phase 3
Indication
In total 11 Indication(s)
Colorectal cancer [ICD11:2B91]
Phase 3
Gastric cancer [ICD11:2B72]
Phase 3
HER2(+) breast cancer [ICD11:2C60-2C65]
Phase 3
Non-small cell lung cancer [ICD11:2C25]
Phase 3
Gastroesophageal junction cancer [ICD11:2B71]
Phase 2
HER2(+) colorectal cancer [ICD11:2B91]
Phase 2
HER2(+) gastric cancer [ICD11:2B72]
Phase 2
HER2(+) solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
HER2(mu) non-small cell lung cancer [ICD11:2C25]
Phase 2
HER2(+) gastroesophageal junction cancer [ICD11:2B71]
Phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Geranyl ketone pyrophosphate oxime ligation
  Linker Info 
Conjugate Type
Site-specific conjugation through the CaaX sequence at the C-terminal.
Combination Type
LBG-MMAF
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  Undisclosed Undisclosed Undisclosed
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
66.70% (> 1.00 mg/kg)
42.90% (HER2-Low)
Patients Enrolled
Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies.
Administration Dosage
FS-1502 was given IV once in 21-day or 28-day cycle at doses of 0.10-3.50 mg/kg.
References
Ref 1 FS-1502, an anti-HER2 ADC, in Patients with HER2-Expressing Advanced Solid Tumors: A Phase 1a Dose-Escalation Study. Cancer Res (2023) 83 (5_Supplement): P4-01-07.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.